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Abstract 
 
The European Academy of Allergy and Clinical Immunology (EAACI) organised the first 
European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring 
together all relevant stakeholders and decision-makers in the field of allergy, asthma and 
clinical Immunology around an open debate on contemporary challenges and potential 
solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White 
Paper aiming to integrate the Academy’s output with the perspective offered by EAACI’s 
partners. This collaboration is fundamental for adapting and integrating allergy and asthma 
care into the context of real-world problems. The Strategic Forum on Allergic Diseases 
brought together all partners who have the drive and the influence to make positive change: 
National and International Societies, patients’ organisations, regulatory bodies and industry 
representatives. An open debate with a special focus on drug development and biomedical 
engineering, big data and information technology and allergic diseases and asthma in the 
context of environmental health concluded that connecting science with the transformation of 
care and a joint agreement between all partners on priorities and needs are essential to 
ensure a better management of allergic diseases and asthma in the advent of precision 
medicine together with global access to innovative and affordable diagnostics and 
therapeutics. 
 
 
Key words: asthma, allergic diseases, big data, environmental health, exposome, 
implementation science, quality criteria, translational research 
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EU = European Union 
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HTA = health technology assessment  
INSERM = The French National Institute of Health and Medical Research  
MDGs = Millennium Development Goals  
NCDs = non-communicable diseases 
PEI = Paul Ehrlich Institute  
PID = primary immune deficiencies  
SDGs = Sustainable Development Goals 
UEMS = Union Européenne des Médecins Spécialistes 
UN = United Nations 
WHO = World Health Organisation  
 
 
 
Introduction 
 
Allergic diseases and asthma represent one of the most frequent chronic diseases 
worldwide encurring a significant economic burden and impairment in the quality of life (table 
1) [1]. 
 
Table 1 : key epidemiologic data for the major allergic diseases 
  Reference 
Asthma 339.4 million people worldwide affected by 
asthma.  
3.6% increase in age-standardised prevalence 
since 2006 
23.7 million DALYs globally. 
23rd (global) and 31st (LMICs) among the 
leading causes of premature mortality  
2016, the Global 
Burden of Disease 
study 
Allergic rhinitis Affects up to 40% of the population worldwide.  
High prevalence in the developed nations of the 
Northern Hemisphere, with 23-30% affected 
population in Europe and 12-30% in the USA.  
Great diversity of prevalence in the non-
Western populations of the Southern 
Hemisphere, with wide inter- and intra-regional 
EAACI Global Atlas 
of Allergic rhinitis 
and chronic 
rhinosinusitis 2016 
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variations ranging from 2.9% to 54.1% between 
countries. 
Atopic dermatitis Point prevalence in adults in the overall/treated 
populations was 4.9%/3.9% in the US, 
3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 
2.1%/1.5% in Japan. 
15-20% of children; the incidence has in-creased 
by 2- to 3-fold during the past decades in 
industrialized countries. 
Continues to increase in prevalence, specifically 
in young children (age 6-7 as compared to age 
13-14 years) and in low-income countries, such 
as Latin America or South East Asia 
Barbarot S, et al. 
Allergy. 
2018;73(6):1284-
1293 
ISAAC phase I and 
III 
Food allergy In Western countries, challenge-diagnosed food 
allergy reported to be as high as 10%, with the 
greatest prevalence noted among younger 
children.  
There is also growing evidence of increasing 
prevalence in developing countries, with rates of 
challenge-diagnosed food allergy in China and 
Africa reported to be similar to that in Western 
countries.  
Loh and Tang, Int J 
Environ Res Public 
Health. 2018 ; 
15(9): 2043. 
Drug allergy True prevalence unknown  
The majority of currently available 
epidemiologic studies report  adverse drug 
reactions which account for 3 to 6% of all 
hospital admissions and occur in 10 to 15% of 
hospitalized patients 
8.3% (range across studies 0.7-38.5%) self-
reported drug allergy. 
Thong and Tan, Br J 
Clin Pharmacol. 
2011; 71(5): 684–
700 
Sousa-Pinto, Ann 
Allergy Asthma 
Immunol. 
2017;119(4):362-
373 
 
 
On 17 November 2018 the European Academy of Allergy and Clinical Immunology (EAACI) 
organised the first European Strategic Forum on Allergic Diseases and Asthma in Zurich, 
Switzerland. The main aim was to bring together all relevant stakeholders and decision-
makers in the field of allergy, asthma and clinical immunology around an open debate on 
contemporary challenges and potential solutions for the next decade. The Strategic Forum is 
an upscaling of the EAACI White Paper [1], launched in May 2018, a collaborative effort of 
the EAACI family, Sections, Interest Groups and Working Groups and patients’ 
organisations, offering a critical view on the allergic diseases and asthma landscape in 
Europe together with an informed analysis of future trends and needs, while identifying and 
promoting research priorities in allergy, asthma and clinical immunology, setting the 
standards and quality criteria and providing guidance and training for practice and research. 
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Allergic diseases and asthma management – the power of partnership 
 
All EAACI stakeholders are key companions actively involved in all EAACI platforms, from 
development and implementation of the EAACI scientific and educational output to joint 
advocacy efforts. Working together with National and International Societies, patients’ 
organisations, regulatory bodies and industry representatives is crucial for promoting good 
clinical practice, high standards of education and outstanding research within Europe and 
worldwide. Our partners’ perspective is fundamental for adapting and integrating the 
Academy’s output into the context of real-world problems. 
 
 
World Health Organisation (WHO): According to WHO non-communicable diseases 
(NCDs) such as diabetes, cancer and heart diseases are  one of the ten threats for global 
health in 2019 and are responsible for 70% of deaths worldwide. The collaboration of 
academic institutions is critical for the implementation of WHO’s public health guidelines 
mandate. Joint activities will improve management of allergic diseases and asthma and 
reduce the burden of the disease together with more efficient use of limited resources. The 
consumption of a healthy diet and achievement of an excellent nutritional outcomes is vital 
for all populations at all stages of the life course, influencing metabolic and immunological 
reactions.  
1. Breastfeeding has a major role in the prevention of atopic dermatitis, asthma, allergic 
rhinitis and food allergies [2,3]. The promotion, protection and support of exclusive 
breastfeeding should be a key element of the public health strategies of all countries 
to reach the target of at least 50% exclusive breastfeeding by 2025 globally [4].  
2. There is increasing public concern on food allergies. Allergen labelling has been 
established for food products and menus [5]. Discouraging self-diagnosis and the 
consumption of unhealthy diets are important preventive and public health actions. 
Correct information to the public and counselling by primary health care 
professionals will be essential [6]. The role of EAACI in promoting good clinical 
practice would be particularly welcome. 
3. Research in clinical immunology contributes to a better understanding of the role of 
different nutrients and foods in modulating the immune response and further help the 
definition of healthy diets [7,8,9]. 
 
 
Paul Ehrlich Institute (PEI): A large amount of clinical data for allergen immunotherapy 
(AIT) products has been generated in recent years. Thus, it is possible to move towards the 
state-of-the-art evidence for safety and efficacy. 
 
1. In 2015 European Medicines Agency (EMA) recognised that there is severe 
heterogeneity in the way allergen products are regulated within the European Union 
(EU), as it is unclear for individual member states which products are on the market 
in which country, which regulatory approach is followed and which requirements are 
demanded for the products [10,11].  
2. During the harmonisation of regulatory approval for allergen immunotherapy two 
major problems were identified: regulatory and procedural issues (e.g. on 
authorisation process, named patient product availability, umbrella authorisation, 
mixed applications) and scientific issues (adequacy in requirements on quality, safety 
and efficacy for rare allergens) [12,13,14]. The Co-ordination Group for Mutual 
Recognition and Decentralised procedures - Human (CMDh) is developing an 
overarching guideline to support harmonisation across EU Member States while the 
Rheumatology/Immunology Working Party/Committee for Medicinal Products for 
Human Use is producing a concept paper (potentially followed by a guideline) for 
allergen products intended for allergies with low prevalence [15,16]. 
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The European Union of Medical Specialists (Union Européenne des Médecins 
Spécialistes (UEMS): Differences in healthcare systems can impact on the mobility of 
professionals and patients, and require harmonisation within European states. There are 
several strategic areas ensuring harmonisation for the management of allergic diseases: 
1. Training of specialists with 3 key pillars: European Training Requirements (ETRs), 
European Assessments (Examinations) and Visitation of Training Centres. The 
UEMS Council approved the European Programme for training in clinical allergology. 
EAACI and UEMS offer a common written exam, the EAACI-UEMS Knowledge test, 
that is revised and certified also by an external professional institution, the Institute of 
Medical Examination in Berne, Switzerland (IML) 
2. CME (continuous medical education) and CPD (continuous professional 
development). The European Council on CPD is meant to bring together all the 
constituents which work closely with international licensing and accreditation 
authorities, and on the other side UEMS sections and boards as well as European 
scientific societies. This discussion forum started in October 2017 last year and is 
organised each year with the aim to solve several areas of overlap between the CME 
and the medical training and licensing.  
3. Quality assurance in medical practice. The UEMS model is to ensure that the 
medical profession retains the responsibility for the key pillars supporting high quality 
of care: medical regulation, certification and registration, education, fitness to 
practice, standards and ethics. 
 
To support the best training and delivery of high-standard care for allergic diseases and 
asthma the UEMS Section and Board on Allergology together with EAACI advocates the 
status of a full specialty of allergology in each European country [17,18]. 
 
 
The European Federation of Allergy and Airways Diseases Patients' Associations 
(EFA): The crucial role of patient involvement is fully recognised today and there have been 
great strides in the promotion and organisation of self-management [19,20,21,22]. However, 
the progress is patchy, participation is resourced unequally, there is not sufficient investment 
in the prevention for allergy and asthma and no coordinated preventative advice for patients. 
In addition, food allergen thresholds and labelling regulations need further implementation, 
there is confusion on consumer choice and patient needs and scarce research community 
interest. The following key pillars support EFA advocacy efforts to improve the lives of 
people with allergy and asthma: 
 
1. Prevention through healthy environments and lifestyle focusing on the quality of 
indoor and outdoor air, precautionary labelling of food allergens, patients as “food 
detectives”, tobacco ban, chemicals exposure regulation, etc. 
2. Access to timely and high-quality health and social care, including digital health-care 
and patients’ involvement in health technology assessment (HTA) 
3. Patient participation as individuals but also as patient groups in prevention, care and 
research through capacity- and patient evidence building 
4. Cure through participatory and meaningful research and big data sharing in allergy, 
asthma and COPD. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The French National Institute of Health and Medical Research (INSERM) considers 
allergies amongst its priorities due to increasing prevalence and costs. 
 
1. Air pollution, tobacco smoke and ambient temperatures rise due to environmental 
and climate changes, affecting pollen and moulds counts, and stinging insect 
numbers are well-known avoidable risk factors for allergic disease [23,24] 
2. Intensified multidisciplinary and translational research is needed to elucidate the 
aetiology of allergic diseases and asthma, underlying mechanisms, treatment, 
management and cost-benefit of action [1, 25,26] 
3. Implementation of the exposome approach incorporating both environmental and 
socioeconomic determinants of the allergic condition has the potential to enable 
comprehension of the allergy epidemics and help planning better interventions for 
prevention or control [27,28] 
4. Lobbying for a healthier environment for allergic patients is urgently needed. 
Adopting and enforcing the WHO standards on chemical air pollution or greenhouses 
gases to lower their emissions and stop climate change together with measures 
lowering indoor air pollution, allergen and drug exposures and banning tobacco 
smoke will certainly help in the near future the management of allergic diseases and 
asthma. 
5. National allergy action plans promoting primary and secondary prevention of allergic 
diseases are equally top priority 
 
 
European Respiratory Society (ERS): Healthy lungs are a cornerstone of human health. 
Globally, respiratory diseases pose an immense worldwide health burden. Five of these 
diseases, including asthma, are among the most common causes of severe illness and 
death worldwide. By raising the profile of lung science, education and advocacy we can 
improve the care for chronic respiratory diseases in Europe and worldwide [29]. 
1. Encouraging health care provider and patient engagement in a multidisciplinary 
approach and ensuring that lung health is accessible for all is a major goal to be 
reached in the near future 
2. Healthcare systems should be proactive rather than reactive and ideally, they should 
include national programmes for all the main respiratory diseases. 
3. Comprehensive disease registries and collaborative Pan-European centre-based 
networks will ensure prospective collection of high-quality real-life data. Stronger 
surveillance systems are also highly necessary [30, 31,32]. 
4. Presently, collaboration   in   Europe   lacks   a   strong   strategic   scientific   
framework    for tackling chronic diseases.  We need a scientific, research and 
innovation platform in Europe to consolidate expertise and resources across borders, 
providing significant added value. 
 
 
European Pediatric Association (EPA/UNEPSA): Over the past few decades the 
epidemiology of children’s health has changed significantly. Global Millennium Development 
Goals (MDGs) allowed to reduce the under-5 mortality rate (with the smallest reduction of 
death rate among the 15-19 years old). Sustainable Development Goals (SDGs) shift the 
efforts towards a holistic, child-right oriented, multisectoral, prevention-based life course 
approach. Accordingly, the new goal for the professional community is innovative research 
and evidence-based data collection to help our patients of paediatric age to develop and 
thrive to achieve their best potential. Child health programming from pre-conception to 
adolescence and youth years should be the focus of professional paediatric caregivers, 
community and families living in Europe, adapted to a wide range of diversities in life style, 
economic status, health care systems, personal beliefs and religions. Academia should lead 
the way to ensure for all European children equal rights to the highest levels of quality of 
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care, while harmonising the heterogeneous systems of paediatric care and education across 
Europe. The following directions were highlighted as essential: 
 
1. Translation of guidelines into clinical practice, big data collection, open collaboration 
and cooperation, join audit programmes and quality criteria are essential to improve 
the quality of care for pediatric patients with allergic diseases and asthma [33,34,35].  
2. New technologies will provide an opportunity to improve allergic diseases control and 
quality of life of both the patient and family members, and reduce the frequency of 
exacerbations. 
3. The “one voice speaking paediatricians and allergists initiative” developed based on 
harmonised best practice in the management of allergy and asthma for paediatric 
patients across Europe  
 
 
 
European Society for Immunodeficiencies (ESID): Joint initiatives and alliances with 
societies with common interests and collaboration between clinicians, scientists and patients 
will ensure better management of patients with immune deficiencies. 
 
1. A novel approach with focus on immune dysregulation not just immunodeficiency is 
necessary in the near future [36] 
2. Registry based studies provide the platform where molecular technologies meet the 
clinical data for diagnosis & treatment 
3. Raising awareness on primary immune deficiencies (PID), providing support for 
better management, networking to share knowledge & expertise and working closely 
with nursing & patient groups, enthusing the next generation of leaders in PID 
practice & research throughout Europe through education and focusing on less well 
served countries are key pillars for better PID care [37] 
  
 
The Global Alliance against Chronic Respiratory Diseases (GARD): Preventing and 
controlling chronic respiratory diseases and keeping them on the global health agenda, will 
require the ongoing energies of all stakeholders. Thus, the following areas should be 
prioritised: 
 
1. Support for countries in the format of a network through which collaborating parties 
combine their strengths, thus achieving results that no partner could obtain alone [38] 
2. Asthma and preventable deaths. According to the Global Asthma Report 2018 
asthma kills around 1000 people every day and affects as many as 339 million 
people and prevalence is rising [39]. Low- and middle-income countries 
disproportionally suffer the most severe cases. Effective treatments for asthma are 
often unavailable or unaffordable as many governments have overlooked asthma in 
their plans to address NCDs. Although asthma mortality rates have decreased in 
many countries over the last decade, avoidable asthma deaths are still occurring due 
to inappropriate management of asthma. Asthma is a major but remediable global 
health problem: two of the five interventions adopted by WHO to tackle NCDs – 
tobacco control, and essential medicines and technologies will directly reduce the 
worldwide burden of asthma [7]. However, the focus of the United Nations (UN) 2030 
Strategic Development Goals on mortality alone does not capture morbidity and the 
imperative to reduce the worldwide burden of asthma. In addition, asthma monitoring 
needs to be ongoing and widespread as half of the world’s countries have never 
studied the prevalence of asthma.  
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3. There is a need to support the transformation of the health care system with use of 
mobile Health and self-care, health literacy and for embedding the environment (air 
pollution, aerobiology) and work/school productivity in the integrated care pathways 
[40,41].  
 
 
 
Research priorities for allergic diseases and asthma 
 
Agreeing on future research priorities in allergic diseases and asthma implies both 
responsibility and vision. Where and how to best use the diminishing resources of funding 
bodies and private investors, as well as good coordination of the commitment and efforts of 
researchers are highly challenging tasks nowadays. It is also difficult to reconcile the 
predictable development of current research with unpredictable external factors such as new 
epidemics, new discoveries of our and other disciplines or with changes in the leadership of 
research in Europe and in the global world of science. Thus, EAACI decided to share this 
responsibility and vision with a wider Think Tank by defining five research priorities, open to 
public consultation and input from key opinion leaders from different scientific institutions 
asking them to prioritise topics selected and to suggest new ones (Table 2) and to call on a 
Strategic Forum to share its vision with all stakeholders. 
 
 
Table 2: Outcome of EAACI survey to worldwide key opinion leaders on research 
priorities for allergic diseases and asthma 
Prioritisation of research areas in allergic diseases and asthma  
 
1. Translational research and implementation science  
2. Drug development and biomedical engineering 
3. Big data and information technology (including mobile health)   
4. Allergic diseases and asthma in the context of environmental health 
5. The developmental exposome 
Additional research challenges emerging from the survey 
 
1. Social and economic impact of allergic diseases 
2. Organization of health care services and access to cures 
3. The impact of a precision approach 
4. Patient participation in health policies and disease management 
 
All topics were discussed during the lively debate at the Strategic Forum with a special focus 
on drug development and biomedical engineering, big data and information technology and 
allergic diseases and asthma in the context of environmental health. 
 
 
Translational research and implementation science 
 
All Forum participants agreed on the key role of translational research fostering the 
multidirectional and multidisciplinary integration of basic research, patient-oriented research, 
and population-based research, with the long-term aim of improving the management of 
allergic diseases and asthma [1,42,43,44, 45,46]. (figure 1). Implementation science was 
also evaluated as a key tool for identifying all major contributions to health care, from 
individual factors up to policy and public health interventions. Several effective strategies to 
implement evidence-based practices such as planning, education, financing, restructuring, 
quality management, and attention to policy context were highlighted (figure 2). This 
approach can support the adaptation of the precision medicine approach in a wide range of 
health care systems facilitating patients access to new drugs or other interventions based on 
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precise endotyping that poses at present significant problems on the sustainability of the 
healthcare system [40, 47,48]. 
 
 
Drug development and biomedical engineering 
 
Advanced therapies such as gene therapies, cell and tissue therapies, regenerative 
medicine, the increasing number of biologicals and biosimilars will soon exceed the number 
of chemical drugs. These therapies together with the introduction of sophisticated devices 
and biomedical engineered products, all call for a new approach to drug development, 
evaluation and monitoring [1,49,50,51,52,53]. The high costs of developing new medicines, 
the low probability for a new product to fulfil the strict regulatory requirements to obtain 
market authorization and, finally, the financial constraints of most national health services 
that cannot afford reimbursement for extremely expensive drugs, represent limiting factors 
for investments in the pharmaceutical area and patient access to new safe and effective 
drugs. Standard operational procedures and quality criteria should be harmonized among all 
countries, including those with an emerging pharmaceutical industrial market such as India 
and China. 
 
 
Following a lively debate on how to improve the process of drug development, biomarkers 
and companion diagnostic for allergic diseases and asthma the participants agreed on 
several priorities (Table 3). If we think globally we should also consider the low-income 
countries. Although the governments seek cheap and simple biomarkers which will predict 
the response we must convince them that the precision medicine approach albeit costly at 
the first evaluation will prove very rewarding in terms of expenditure by better selection of 
responders and by reducing adverse events and associated healthcare costs. All world 
citizens should have access to new safe and effective drugs by developing models that, 
reducing the risk of investments, eventually reduce the price of new medicines, and by 
establishing heath policies on the basis of reasonable priorities and social equanimity. 
 
 
Table 3: Proposed innovative approach for the development of cutting-edge therapies for 
allergic diseases and asthma – the 5 year plan 
 
1. Early collaboration of all stakeholders in drug development 
2. Joint health technology assessment scientific advice 
3. Novel standard and quality criteria adapted to the concept of precision medicine 
4. Development of validated biomarkers and companion diagnostics that enable the 
dissection of heterogeneous diseases into well-defined phenotypes and endotypes 
5. Adaptive pathways for drug development that allow evaluation and monitoring 
during the entire life-cycle 
6. Different approach in terms of systematic nomenclature of allergic diseases shifted 
towards new mechanisms instead of description of symptoms 
 
 
The regulatory tools already exist, so what is needed is better guidance on how to address 
the precision medicine approach at an operational level while interlinking different aspects. 
For example, if our community seeks faster development of new drugs we need to prove 
how this will ensure better translation into clinical practice. The regulators have learned that 
“the one size fits all” approach is not working so if Academia proposes a cost-effective 
process for precision medicine that will be working in daily practice, the regulators might 
accept it.  
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Big data and information technology 
 
Healthcare is at present largely based on evidence provided by randomised controlled 
clinical trials and observational/epidemiological data in selected populations. There is 
however a massive amount of data available from healthcare records, registries, and 
biobanks whose potential in improving knowledge has not yet been fully explored. The 
availability of new information technology techniques for collecting, analysing and relating 
the “big data” provided 
by the real world opens new horizons to a new, more comprehensive knowledge. Rapid 
learning systems can shape vast amounts of “omics” (genomics, proteomics, metabolomics, 
catalomics, phenomics, etc.)  together with collecting “real-world” data unbiased by any pre-
selection criteria to support real-time clinical decision support at the point of care leading to 
harmonised care based on quality criteria. The availability and analysis of big data is 
expected to open a new era in the computing science, with profound effects also in the area 
of biology and medicine. Computers will not only be instruments to provide answers by 
elaborating data on the basis of pre-defined algorithms, but will be able to learn themselves 
from data analysis (machine learning or artificial intellingence) and to provide solutions on 
the basis of original algorithms [54-71]. Modern telemonitoring systems combined with 
artificial intelligence can  accurately predict asthma exacerbations with the potential to 
improve self-management interventions [72-74] (figure 3). 
 
However, big data are quite heterogeneous and come from a large variety of sources [75]. 
Their quality should be carefully checked and new hypotheses deriving from big data should 
be experimentally tested before neglecting the actual evidence and adopting new diagnostic 
and therapeutic approaches. There is clearly a huge job to be done in upskilling the 
healthcare providers, and it’s a matter not only of skills but also of attitudes and culture, 
which are harder to change. Electronic records linked to multiple and quality assured 
databases are essential, but there is also a big need for bio-informaticians who can ensure 
that the data available is of, high-quality, and well managed. In addition, efficient usage of 
big data requests that industry, 
regulatory bodies, scientists and clinicians accept transparency policies which make their 
data available to the community via open platforms 
 
A significant shift in the doctor-patient relationship is expected with the well-informed patient 
advocating for their own care and connected in real time with the healthcare provider who is 
provided with personalised information from patient portals. Artificial Intelligence will certainly 
favour not only a tremendous progress in medical sciences, but will the creation of a new 
relationship between humans and machines with relevant implications in ethics and 
responsibilities of the medical profession. Moreover, big data imply a risk for citizens’ and 
patients ‘privacy. This should be protected by adequate regulations and accurate 
anonymization techniques of individual personal data algorithms [76,77].  
 
Allergic diseases and asthma in the context of environmental health 
 
Natural and man-made environments such as air quality, water and soil, together with all the 
physical, chemical, biological and social features of our surroundings have a major influence 
on the control and severity of allergic diseases and asthma [28,78,79]. Although the 
precision medicine revolution has the potential to transform environmental measures we still 
have a long way to go to more effectively identify what or whom should be targeted. Some 
environmental interventions like air quality regulation cannot be targeted to any subgroup, 
genetic, or otherwise. Others, like breastfeeding, vaccination, antismoking campaigns, 
exercise, or diets, can be targeted, but they need to prove practical and/or cost efficient. The 
most efficient prevention strategies would identify those at highest risk of disease following 
avoidable exposures. However, simply evaluating genetic risks is not sufficient since we 
need to co-factor the interaction with environment. An improved methodological approach 
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proving causality instead of associations together with an integrated surveillance network for 
the environment impact on allergies and asthma are key pillars to move this field forward 
[28,80,81]. 
 
The importance of functional foods and nutraceuticals is expanding globally in terms of 
scientific services, legal aspects, and marketing strategies for health promotion, reduction of 
disease, and health care costs [82, 83]. Nonetheless, they are marketed without a 
prescription and their safety and efficacy is yet to be proven, especially if consumed in 
supra-dietary doses as nutritional supplements. 
 
Urgent and concerted actions are needed to improve the European legislation on 
environment control, with a special focus on air quality, tobacco banning, indoor and outdoor 
pollution, invasive allergenic plants and standard occupational exposure. 
 
All participants agreed on “The One Health concept” evaluating the interconnections 
between human, environment and animal health and food and water safety is being 
particular amenable for the prevention and better management of allergic diseases and 
asthma in the future [84,85].  
 
 
The developmental exposome 
 
Multifactorial diseases such as allergic diseases and asthma involve the combined effects of 
genetic factors, development-specific exposures (in utero, early-life and childhood 
exposures) and the biological responses to those exposures (allostasis) [28,86-95]. 
Many epidemiological, genetic, environmental, and immune risk factors for allergic diseases 
and asthma are described, however, distinguishing which risk factors are causal, their 
mechanism of action and how interaction between these factors initiates disease remains 
poorly understood. Although it is recognized that up to 90% of allergies and asthma results 
from development-specific exposure with a secondary role of the genetic background 
significantly less research is oriented towards describing the developmental exposome. 
Current barriers to our understanding include the limitations of research during gestation and 
the perinatal period, inadequacies of animal models in recapitulating the onset of human 
disease, differences between human and experimental animal developmental stages and 
difficulties in documenting low dose exposure (limited by the sensitivity of the assay), 
intermittent exposure (limited by the frequency of testing) and transient exposure (the 
system should be in place at the time of the exposure). 
 
Both primary prevention based on molecular endotypes and the developmental exposome 
can be prospectively validated using evidence-based clinical management to improve care 
across the severity spectrum. Investigators with expertise in molecular biology and 
exposomics need to engage in research planning with experts in informatics, genetics, 
clinical, health-economics and drug development experts. User-friendly large datasets will 
support this cooperation. 
 
The exposomic approach is particularly applicable to the study of environmental causes of 
allergic diseases and asthma as it provides risk profiles instead of single predictors.  
However, we still lack validated criteria for selecting the best assay(s) to assess biological 
response for the research question of interest, easy to implement guidelines for sample 
collection and standards and quality criteria for repositories and biobanks [28,96]. 
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Patient participation in health policies and disease management 
 
All participants stated their strong belief in the patients’ role as equal partners with health 
professionals in the management of their condition, involved in all steps, from research to 
daily healthcare. Patients are often active people who can, if adequately supported and 
according to their individual capabilities and situation, make a difference for the sustainability 
of environmental policies and healthcare systems [97,98].  
 
The five “Ps” of modern healthcare (patient-centered, prompt, personalised, pathway-
oriented, portable) and the 5 “Es” of patient empowerment (education, expertise, equality, 
experience and engagement) were discussed as corner-stones in implementing better 
management pathways for allergic diseases and asthma. 
 
 
Conclusion and future directions 
 
The European Strategic Forum on Allergic Diseases organized by EAACI provided a 
platform where ideas, thoughts and questions were tackled in an open environment, in full 
alignment with the EAACI belief that progress happens only by bringing together all partners 
who have the drive and the influence to make positive change (figure 4). 
 
The One Health approach, integrating the technological progress in different disciplines, the 
exposomics and cross-omics approach, and system biomedicine, represents a major 
challenge for research in allergic diseases and asthma. This implies a growing importance of 
computing science for big data storage and analysis. 
 
Connecting science with the transformation of care is necessary is necessary to ensure that 
the precision medicine tools will facilitate a better management of allergic diseases and 
asthma.  A special focus is advocated for translational research and implementation science, 
big data and artificial intelligence, “omics”-technologies facilitating personalised therapeutic 
and prevention approaches, harmonisation and standardisation of the clinical care 
pathways, novel training competencies and clinical decision systems, investment into smart 
E-health and M-health programmes and continuous support for patient participation in health 
policies and disease management (figure 4). 
 
To ensure that progress in research is reflected into a real advance in healthcare and 
nothing is “lost in translation”, a close collaboration of all stakeholders is needed to define 
priorities and unmet needs as well as to enable a global access to innovative and affordable 
diagnostics and therapeutics. 
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